Lysosomes are key cellular catabolic centers that also perform fundamental metabolic, signaling and quality control functions. Lysosomes are not static and they respond dynamically to intra-and extracellular stimuli triggering changes in organelle numbers, size and position. Such physical changes have a strong impact on lysosomal activity ultimately influencing cellular homeostasis. In this review, we summarize the current knowledge on lysosomal size regulation, on its physiological role(s) and association to several disease conditions.
| INTRODUCTION
Initially described by Christian de Duve, 1,2 lysosomes are key mediators of protein degradation with a pivotal role in the coordination of cellular metabolism and intracellular signaling. 3 Lysosomes participate in many biological processes, including antigen presentation, plasma membrane repair, exosome release, cellular adhesion and migration, apoptosis, gene regulation, tumor invasion and metastasis (reviewed in References [3] [4] [5] ).
The complexity of lysosomes is emphasized by data from proteome analyses: ion channels and transporters regulate the luminal ion composition, 6,7 a dedicated H+-ATPase maintains the luminal acidic pH, 8, 9 tethering factors and SNARE proteins at the membrane control fission and fusion with communicating cellular compartments. 10, 11 In addition, around 200 glycosylated and non-glycosylated integral membranes proteins fulfill several critical functions including, for example, the transport of metabolites and the protection of the organelle membrane from degradation. 5, 12 In response to diverse intra-and extracellular stimuli, lysosomes continuously adjust their numbers, size and position. It has been previously demonstrated that the localization and motility of those organelles significantly affect their activity. 13, 14 Compromised lysosomal positioning is associated with detrimental effects present in several disease conditions, most prominently cancer. [15] [16] [17] It is also intuitively clear that changes in lysosome number influence the degree to which a certain function can be performed. Interestingly, among the different parameters, the contribution of lysosomal size remained somewhat obscure. Does size matter and if so, to what extent is it linked to organelle numbers?
Various terms are used to differentiate specific intracellular compartments, including organelles of the endocytic and autophagic routes. For clarity reasons, we would like to define the terms used in this review. Late endosomes fuse with terminal lysosomes forming a hybrid compartment called endolysosome. 18 Endolysosomes and terminal lysosomes coexist in a dynamic equilibrium that is maintained by lysosomal reformation. 19 Unless otherwise stated, we use the term lysosome to identify both endolysosomes and lysosomes, jointly corresponding to very late stages-frequently the very end of the endocytic pathway. Whenever necessary, endolysosomes and terminal lysosomes are discriminated as such. As far as autophagy is concerned, autolysosomes arise from the fusion of autophagosomes with lysosomes. 20 In the following, we recapitulate general aspects of lysosomal geometry and size, based on two-dimensional (2D) electron microscopy (EM) snapshots, morphometric measurements, counts and calculations. As already demonstrated by the pioneers in the field, 21 terminal lysosomes are typically spherical organelles, appearing as round or ovoid/elliptical section profiles (eg, Figure 1A ), with occasional, short-lived tubular extensions (eg, during lysosome reformation 22 ). For practical reasons, we exclude the less common, tube-shaped lysosomes 22, 23 from the following considerations. EM-based morphometry 24 is unique in providing a solid basis for the precise detection of even moderate qualitative and quantitative alterations of organelle ultrastructure, especially when cryo-fixation methods 25 are used for sample preparation. Cryo-fixation also traps transient and/or labile membrane configurations 26, 27 and efficiently prevents uneven artifactual organelle shrinkage, that selectively affects different maturation stages of endocytic compartments. 28 To mention an exemplary case, HT1080 cells (human fibrosarcoma cell line carrying an N-ras mutation 29 ) have globular lysosomes with an average diameter of 410 nm. 30 In contrast, lysosomes of HT1080 cells, where components of the BORC (BLOC-1 related complex) complex have been deleted by CRISPR/Cas9 genome editing, are only 311 nm wide (Figure 1 and Reference 30). Further discussion of this difference follows later in this article. Although a ≈25%reduction of organelle diameter might appear minor at first glance, simple arithmetic allows the conversion of the 2D-value into 3D-reality. As illustrated in Table 1 , a 25% diameter reduction yields about half the surface area or the volume of spherical organelles-a quite relevant physiological difference. Bearing this F I G U R E 1 Electron micrographs of snap-frozen lysosomes displaying general morphology and size variations of the almost spherical organelles in HT1080 human fibrosarcoma cells. The term lysosome is used in a broad sense comprising both terminal lysosomes resulting from cargo endocytosis as well as autolysosomes. Those organelles are characterized by an opaque matrix, containing frequently more or less degraded (membrane) material and/or a completely electron-dense core. A, Under wildtype conditions the lysosomal diameter (white arrow) is on average 400 nm. B, After deletion of BLOC-1 related complex (BORC) the mean diameter decreases to approximately 300 nm; m = mitochondrion; scale bar = 400 nm basic geometry in mind, we will now discuss additional aspects of lysosomal size variations.
First, size represents a physical constraint determining the ratio between membrane surface area and organelle volume. Early work on the yeast syntaxin homolog Pep12 indicated that this SNARE is essential for fusion of endocytic vesicles. Pep12 deletion is phenotypically characterized by an accumulation of small, 40 to 50 nm vesicles in the cytoplasm and an inflation of the vacuole, 31 the yeast equivalent of lysosomes and plant vacuoles. Importantly, the limited volume of the endosomes effectively prevented intraluminal vesicle formation, 32 blocking transport of ubiquitinated cargo towards the vacuole. 31, 32 In addition, this structural defect also impaired the recruitment of hydrolases, leading to an acidification defect and concomitant enlargement of the vacuole.
Second, size regulates dynamics. In 2014, Bandyopadhyay et al addressed the influence of lysosome diameter on the transport of organelles in living cells. 33 In brief, active transport occurred within a broad range of velocities and was not affected by organelle size. In contrast, the diffusive component of lysosomal movement inversely correlated with the organelle size. 33 In addition, it has been shown that increased lysosomal size negatively influences exocytosis. 34 Enlarged lysosomes in fibroblasts from Chediak-Higashi patients as well as from beige mice displayed reduced exocytosis that could be reverted by treatment with E-64d, a protease inhibitor, reducing lysosomal size in those cells. 34 Mechanistically, E-64d treatment protects PKC from ceramide-induced, calpain-mediated degradation thereby reducing lysosomal size. 35 The protease inhibitor also increases lysosomal elastase and cathepsin G activity. 35 These results imply that the impaired exocytosis observed could be attributed to the abnormal size of lysosomes.
Importantly, since lysosomal size is altered in several human diseases this might directly or indirectly contribute to the pathophysiology of the different conditions. Below, we summarize the current knowledge of factors contributing to the regulation of lysosomal size and frequency and describe human disorders associated with alterations of endolysosome-, phagolysosome-and/or lysosome-size. In Figure 2 we schematically guide the reader through the following chapters and introduce key components and protein machineries of late endosomes/lysosomes/autophagosomes and their involvement in the regulation of organelle size. Importantly, the rate of acidification is not uniform among terminal endocytic organelles, strongly depending on the organelle's position within a cell 36 and on its role within the reformation cycle. 19 In brief, terminal lysosomes are only moderately acidic, smaller and acidhydrolase inactive, whereas endolysosomes tend to be bigger, acidify and are catabolically active. Although not formally proven, it has been proposed that pH fluctuations might facilitate the function of lysosomal enzymes with neutral or alkaline pH optima. 37 Inhibition of the V-ATPase blocks the transport of endocytic markers from early endosomes to more acidic organelles. In other words, the V-ATPase is required for the formation of intermediate compartments between early and late endosomes, generally designated as multivesicular bodies (MVBs). 38 In addition, it has been proposed since two decades that the V-ATPase regulates both fission and fusion events, thereby contributing to the control of the lysosome/vacuole size (Figure 2A formation generates a proteolipid fusion pore that facilitates membrane fusion. [44] [45] [46] Although this view has been strengthened by subsequent reports, 43, 47 the mechanistic details of this regulation and the importance of acidification in fusion remain controversial. 44, 48 In higher eukaryotes, the V-ATPase seems to fulfill a regulatory role, not being intrinsically necessary for all lysosomal fusion events. As an example, it has been demonstrated that the V 0 domain of the V-ATPase regulates exocytosis of synaptic vesicles in higher eukaryotes. 49, 50 In contrast, in macrophages the V 0 domain was not required for phagosome-lysosome fusion. 51 Mammary gland involution provides another impressive example of the importance of acidification in the control of lysosomal size and numbers. This regulated tissue remodeling process strongly depends on lysosomal acidification and biogenesis to mediate the conversion of the lactating gland to a prepregnant state. Recent work revealed that loss of the Zinc transport 2 (ZnT2) prevents the assembly of the V-ATPase on lysosomes, reducing the number of organelles as well as their size and ultimately impairs lysosomal mediated cell death that would be required for involution. 52, 53 3 | PI METABOLISM AND ORGANELLE SIZE Weak base compounds like Chloroquine were some of the first agents found to trigger swelling of lysosomes, 54 followed by experiments using Wortmannin. 55 In melanoma cells, the latter one, a PI 3-kinase inhibitor, leads to inflation of the organelles in a process dependent on endocytic membrane influx. Importantly, Wortmannin inhibition also triggers a decrease in the number of intraluminal vesicles of MVBs. 55 These observations, highlighted the importance of phosphatidylinositol-3phosphate (PtdIns(3)P) the product of PI3K activity, in maintaining the size and structure of late endocytic organelles. Interestingly, PtdIns(3)P levels also control autophagosomal size. 53, 56 Two decades ago, PtdIns(3)P was found to accumulate within MVBs. 57 Among the different PtdIns(3)P effectors, the hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) is a member of the endosomal sorting complex required for transport complex 0 (ESCRT-0), contributing to the sorting of cargo marked with ubiquitin into intraluminal vesicles, 55, [58] [59] [60] (Figure 2A ). retromer recruitment also requires the interaction between its VPS35 subunit and RAB7-GTP. 62, 63 In turn, Rab7 activity is kept in check by TBC1D5, a Rab7 GAP that depends on retromer for its membrane association ( Figure 2C ). 64 Of note, Rab7 hyperactivation, either by overexpression or because of impairment of TBC1D5 function, leads to the formation of enlarged endolysosomes, increased transport of cargo along retromer dependent routes and a decrease of mitophagy. 65, 66 Mechanistically, the increase in Rab7 prevents autophagic lysosome reformation (ALR), thereby triggering the accumulation of enlarged organelles. 22 Like HRS, PIKfyve (also known as 1-phosphatidylinositol 3-phosphate 5-kinase) is a PtdIns(3)P effector that contains an FYVE domain critical for its membrane localization. 67 PIKfyve is the sole enzyme known so far capable of catalyzing phosphatidylinositol3,5-bisphosphate (PtdIns(3,5) P 2 ) out of its precursor. PIKfyve activity triggers a local depletion of PtdIns(3)P and PtdIns(3)P-dependent proteins and the recruitment of PtdIns(3,5)P 2 effectors to the organelle membrane, (Figure 2A,B ).
| V-ATPASE AND ORGANELLE ACIDIFICATION
Earlier studies in Saccharomyces cerevisiae have identified the importance of PtdIns(3,5)P 2 in membrane trafficking. 39, 40, 68 In brief, deletion of yeast fab1, the homolog of human PIKfyve, triggered a severe growth defect and was characterized by the presence of enlarged vacuoles that occupied the majority of the cell. The yeast data led to a model in which PtdIns(3,5)P 2 levels are carefully tuned to maintain the turnover of vacuolar membranes to less mature endocytic compartments, hence, contributing towards the regulation of the organelle's size. 68 Of note, the fact that fab1 mutants display reduced numbers of intraluminal vesicles and Vps24 (a subunit of ESCRT-III) interacts with PtdIns(3,5)P 2 , emphasizes again a tight interconnection in the activities mediated by different PtdIns(3)P effectors, 69 (Figure 2A ).
PIKfyve does not act alone. This phosphoinositide kinase associates with a preassembled arPIKfyve (Vac14) and sac3 (Fig4) complex.
The ternary complex is known as PAS (PIKfyve-ArPIKfyve-Sac3) complex. 70 ArPIKfyve, the structural mediator, maintains the integrity of the complex via homo and heteromeric interactions with the remaining subunits. 71 Overall, the PAS complex is organized to provide optimal PIKfyve functionality. 72 In addition, PAS contains two enzymes with opposing effects, PIKfyve that catalyzes PtdIns(3,5)P 2 production, and sac3 that converts it into PtdIns(3)P. A peculiarity of PAS is that the presence of the phosphatase sac3 is also required for PIKfyve activation. 73, 74 PtdIns(3,5)P 2 is a low abundant lipid, typically accounting for 0.04% to 0.08% of total inositol phospholipids present in human cells. 75 Despite the minute expression levels, PtdIns(3,5)P 2 is an essential lipid species and its depletion in mice, Drosophila melanogaster and Caenorhabditis elegans is embryonic lethal. [76] [77] [78] [79] In mammalian cells, ablation of PtdIns(3,5)P 2 induces an imbalance in endosomal membrane homeostasis resulting in the enlargement of both early and late endosomal/lysosomal compartments. 80 Interestingly, too much PtdIns(3,5)P 2 can also be detrimental to lysosomal homeostasis. In Raptor. [83] [84] [85] Of note, deletion of Atg18 triggers enlargement of the vacuole that is phenotypically indistinguishable from fab1/PIKfyve ablation. 84 In addition, the presence of PtdIns(3,5)P 2 is recognized by the PX domain containing sorting nexins 1 and 2 (SNX1 and SNX2) 86, 87 and the sec14 domain containing clavesin. 88 Interestingly, clavesin knockdown in neurons also enlarges lysosomal-associated membrane protein 1 (LAMP1) positive structures. 88 In plants, PtdIns to prevent lysosomal reformation with concomitant increase in enlarged endolysosomes. 27 Under these circumstances, organelles coalesce, thereby decreasing their numbers and increasing their size. 94 Both of these processes, retrograde transport and lysosomal reformation utterly, depend on efficient fission. In contrast, the contribution of an imbalanced endocytic pathway to PIKfyve ablation phenotypes seems still a matter of debate with some authors claiming a block in the degradation of both EGFR and c-Met, 91 whereas others observe no clear defects. 80 Mechanistically, the size of an organelle is to a large extent dependent on the rate of membrane exchange, separated in the relative contributions of fusion and fission processes. In lysosomes, high levels of juxta-organellar calcium, released from the intraluminal pool, were detected in the vicinity of fusion/fission sites. Interestingly, PtdIns(3,5)P 2 interacts with the mucolipin transient receptor potential channels (TRPMLs), activating them and promoting calcium transport across the organelle membrane 95 ( Figure 2B ). In a reverse manner, PtdIns(4,5)P 2 was shown to inhibit TRPML1 activity. 96 Of note, TRPML1 deficient cells exhibit enlarged lysosomes/vacuoles and trafficking defects reminiscent of those observed by depletion of PtdIns (3,5)P 2 and overexpression of TRPML1 were sufficient to revert PtdIns(3,5)P 2 deficiency phenotype. 95 This regulatory pathway is conserved in Saccharomyces cerevisiae, where PIKfyve regulates vacuolar size through TRPML1. 97 In 2016, Li et al extended this epistatic alignment and revealed that the PtdIns(3,5)P 2 -TRPML1-ALG-2-dynein signaling cascade is required for lysosome tubulation and reformation 98 ( Figure 2B ). Interestingly, mTORC1 phosphorylation of TRPML1 prevents the activation of the calcium channel when nutrients are abundant, thereby restricting the action of TRPML1 to starvation conditions. 99, 100 In turn, TRPML1 and calmodulin activities are required for mTORC1 reactivation during prolonged starvation 100, 101 ( Figure 2B ). Finally, TRPML1 levels are compromised in patients suffering from Mucolipidosis type IV, a rare lysosomal storage disease triggered by mutations in the mucolipin 1 (TRPML1) gene. For more details on mucolipidosis type IV please see below.
TPC are lysosomal two-pore channel proteins that were initially identified as mediators of nicotinic acid adenine dinucleotide phosphate (NAADP)-dependent calcium release. 7 Later, TPCs were shown to transport sodium upon activation by PtdIns(3,5)P 2 . 102, 103 The ion selectivity properties of TPC remains a controversial topic and might be dependent on the experimental conditions. 104 Importantly, TPCmediated calcium transport was shown to rapidly reduce and reverse the membrane potential, thereby promoting organelle fusion ( Figure 2E ). In accordance to its mode of action, TPC overexpression induced enlarged lysosomes. 102 Surprisingly, unlike TRPMLs, the expression pattern of TPC is restricted to certain cell types indicating that the relative contribution of different ions and transporters to the regulation of lysosomal membrane characteristics might be cell type dependent.
In Saccharomyces cerevisiae, genetically ablated fab1 (PIKfyve), vac14 (arPIKfyve) and vac7 cells have vacuoles with neutral pH, a defect that appears to occur independently of vacuole enlargement 76, 77 and of a possible mislocalization of the V-ATPase. 105 A similar phenomenon was observed in lysosomes of Caenorhabditis elegans and Drosophila melanogaster cells encoding a partially functional PtdIns(3)P 5-kinase. 40 Apparently, at least in yeast, the levels of PtdIns(3,5)P 2 required to support acidification are lower than those required to maintain organelle morphology, indicating that under certain conditions, vacuoles may increase in size without an accompanying acidification defect. 106 In other words, PtdIns ( PtdIns(4,5)P 2 plays a dual role in ALR. On one hand, it controls tubule formation as described above, on the other hand, it is required for the fission of newly formed proto-lysosomes. This second function was uncovered with the observation that deficiency in PIP5K1A, a second kinase generating PtdIns(4,5)P 2, is characterized by the presence of long, stable reformation tubules without vesicle budding. 110 Surprisingly, recent work revealed that PtdIns(4,5)P 2 negatively regulates autophagosome-lysosome fusion. In brief, its production triggers the dissociation of Rab7 and PLEKHM1 from the organelle membrane. 113 Whether PtdIns(4,5)P 2 activates a Rab7 GAP remains to be formally proven. In any case, PtdIns(4,5)P 2 is emerging as pivotal player in the control of both fusion and reformation events actively shifting the balance towards the latter.
Another critical aspect of ALR is the retention mechanism that prevents diffusion of cargo and/or regulatory proteins from the parental autolysosome to the forming proto-lysosome. In PI4KIIIβ depleted cells, lysosomal luminal components were aberrantly found in reformation tubules indicating that PI4KIIIβ actively contributes to retention. 114 In addition, PI4KIIIβ ablation leads to hypertubulation that could only be rescued by expression of the catalytically active form of PI4KIIIβ. These data imply that PI4KIIIβ's control of lysosome tubulation and cargo retention is mediated by PtdIns(4)P. 114 Disturbances in ALR are currently linked to hereditary spastic paraplegia and Parkinson disease. In brief, mutations in spastizin and spatacsin trigger the two most common forms of autosomal recessive hereditary spastic paraplegia. Their ablation leads to the accumulation of enlarged autolysosomes at the expense of lysosomes, a phenotype typical of ALR. 115 In addition, spatacsin knockout mice display loss of cortical neurons and Purkinje cells consistent with a spastic paraplegia-like phenotype. 116 Although not formally proven, it has been proposed that ALR defects may result in a reduction of functionally active lysosomes that in turn would reduce autophagic clearance. 128 as discussed below. Furthermore, knockout of GATOR2 components also impairs lysosomal acidification and triggers an increase in the number of late endocytic organelles. 130 The late endosomal/lysosomal adaptor and MAPK and MTOR activator (LAMTOR), also known as Ragulator, is a pentameric complex that recruits the Rags to the lysosomal membrane, a pre-requisite for mTORC1 activation. 131 Interestingly, LAMTOR knockout cells display increased numbers of late endosomes, lysosomes and autolysosomes that are significantly smaller than their counterparts in control cells. 26, 132, 133 Furthermore, the acidification of lysosomes is apparently normal in LAMTOR depleted cells 133, 134 and they display an increase in late endosomal proteins characteristic of the nuclear translocation of TFEB, constitutive activation of the CLEAR network and a concomitant rise in basal autophagy. 133 Taken together, based on the currently available reports addressing organelle size, LAMTOR and the Rag GTPases epistatically contribute to mTORC1 activation, but their effects on lysosomal size are apparently (diametrically) opposing.
The BLOC-1 related complex (BORC) contains eight subunits (Myrlysin/LOH12CR1, Lyspersin/C17orf59, Diaskedin/C10orf32, KxDL1, MEF2BNB, BLOS1, BLOS2 and Snapin) and was initially found to regulate lysosomal positioning. 135, 136 In 2017, others and we have shown that LAMTOR associates with BORC, negatively regulating BORC and Arl8b dependent transport of lysosomes to the cell periphery. 137, 138 Interestingly, BORC knockout cells display a multilayered deregulation of lysosomal homeostasis. In brief, the most conspicuous defect of BORC ablation is the accumulation of lysosomes in the perinuclear region. 135 Later, it was also found that BORC knockouts show increased autophagic structures and a defect in autophagosome-lysosome fusion 139 (Figure 2D ). In brief, depletion of BORC impaired the recruitment of the HOPS tethering complex to lysosomes (mediated by Arl8b 140 ) and the subsequent assembly of the STX17-VAMP8-SNAP29 trans-SNARE complex involved in autolysosome formation. In addition, the positioning defect observed in these cells implied that lysosomes were no longer mobile and therefore unable to translocate to the cell periphery where most autophagosomes originate. As such, the mobility defect translated into compromised organelle fusion. 139 Recently, Snouwaert et al described a mouse mutant of the BORC subunit Diaskedin with dystrophic axonopathy and motor impairment. The Diaskedin Q87X mice showed swollen axons containing masses of unidentified membrane remnants. 141 In addition to the already described phenotypes, we have recently uncovered that deletion of the BORC subunits Myrlysin and Diaskedin, compromises assembly of the complex on the organelle membrane and triggers a decrease in lysosomal size. 30 BORC regulates PIKfyve-dependent production of PtdIns(3,5)P 2 actively controlling lysosomal reformation. This process requires AMPK, a known PIKfyve activator, 30 and is additionally dependent on LAMTOR/ Ragulator complex ( Figure 2B ). Interestingly, both LAMTOR and BORC knockout cells showed reduced lysosomal size, reaching only about 75% of those in WT cells. 26, 30 Of note, the reduction of lysosomal diameter was associated with increased lysosomal frequency 26, 30 probably reflecting some kind of physiological compensation.
Finally, it is worth mentioning that we observed a further, additive effect on the size reduction of lysosomes in LAMTOR plus BORC double knockouts. 30 These data imply the existence of two independent mechanisms contributing to the observed size regulation.
| DISEASE CONDITIONS WITH ALTERED ORGANELLE SIZE
Below, we describe disease conditions with reported alterations of endolysosomes, autolysosomes or lysosomes. Although we tried to follow in this article the above-mentioned nomenclature, for some of the referred studies, it is unclear to which of the three classes of organelles the authors precisely refer to. Therefore, we decided to Nowadays, it is clear that the spectrum of LSD must also include other genetic alterations that disturb the synthesis and/or transport of lysosomal proteins and cargo and that are causal for the characteristically enlarged structures. Independently of its origin, the accumulation of nondegradable material within lysosomes has a profound impact on the organelle's physiology, size, trafficking and overall degradative capacity. [145] [146] [147] [148] As an example, sphingomyelin accumulation in Niemann-Pick disease cells, blocks TRPML1 and calcium-dependent lysosomal functions. 149 In general, defects on soluble, luminal proteins in lysosomes are more frequent than those triggered by depletion of lysosomal membrane proteins. 150 The lysosomal-associated membrane protein The galactosylceramidase enzyme is directly responsible for the degradation of galactosylceramide and psychosine. A subset of LSD, called lipidoses, display aberrant storage of lactosylceramide derivatives in the endosomal system. Their uptake and sorting to the Golgi apparatus is dependent on intracellular cholesterol levels. 154 This and other observations led to the early recognition that altered lipid synthesis and trafficking contribute to LSD pathology and the characteristic lysolipid accumulations. [155] [156] [157] Interestingly, a reciprocal regulation has also been observed in oligodendrocytes and astrocytes from Krabbe disease patients in which galactosylceramidase deficiency leads to psychosine accumulation that in turn triggers a significantly down-regulation of AMPK activity. This cascade of events culminates in increased biosynthesis of lipids including cholesterol and free fatty acids. 158 Another hallmark of LSD is the accumulation of calcium in the cytosol and depletion of ions from the endoplasmic reticulum (ER).
Although aberrant calcium homeostasis is indeed a common denominator in this disease group, the underlying pathophysiological mechanisms differ among various LSD and can, at least in part, be discriminated based on the accumulated lipids. Whereas glucosylceramide sensitizes the ryanodine receptor to mediate calcium release from the ER, 159 GM1 and GM2 ganglioside accumulation inhibits the reuptake of calcium to the ER by interfering with the function of the responsible transporter (SERCA). 160 In addition, the increase in sphingomyelin observed in Niemann-Pick type A disease triggers a severe reduction of SERCA expression levels, with concomitant accumulation of calcium in the cytoplasm. 161 Finally, mucolipidosis type IV (MLIV) is a rare LSD triggered by loss of function mutations in mucolipin 1 (TRPML1), a lysosomal membrane channel releasing cations. 162, 163 First described by Berman et al, 164 MLIV displays a profound degenerative profile with neurodevelopmental-, psychomotor-, ocular-and gastric-abnormalities. 165 
| Charcot-Marie-Tooth
Charcot-Marie-Tooth disease is a genetically heterogeneous motor and sensory peripheral neuropathy caused by mutations in more than rons and microglia, 175 and it is known that in cortical neurons TMEM106B expression correlates with neuronal maturation. 176 In neurons, TMEM106B knockdown reduces the number of lysosomes.
In a reverse manner, TMEM106B overexpression inhibits organelle transport and leads to the accumulation of large LAMP positive lysosomes in the soma. 175 The presence of inclusion bodies in several immunological cell types, including macrophages, T-lymphocytes, neutrophils and leucocytes serves as diagnostic marker for CHS. 179 Furthermore, it is clear that a defective structure or function of melanosomes in melanocytes is causing albinism, 180 and that the mild bleeding tendency observed in these patients can be explained by the absence of platelet dense bodies. 180, 181 Taken together, CHS pathophysiology roots on defects in the maturation of lysosomes, phagosomes and lysosomalrelated organelles (LRO; eg, melanosomes, cytolytic granules and dense granules), leading to the accumulation of enlarged lysosomes and LRO that cannot be secreted. 182, 183 CHS is caused by mutations in the LYST (lysosomal trafficking regulator) gene. The enormous size of the LYST protein has been a significant hurdle to those attempting to shed light on its function.
Nevertheless, data from LYST homologs in Drosophila melanogaster
and Dictyostelium discoideum indicate that LYST might regulate organelle fusion. [184] [185] [186] Unfortunately, the neurologic phenotypes displayed by LYST-mutant mice were found to depend on genetic background. 187 Nevertheless, the characterization of Lyst-mutant beige mice indicated that LYST controls phagosomal maturation, 
| Treatment options for LSD and related diseases
There is light at the end of the tunnel for those suffering from LSD.
We have seen a rapid increase in our understanding of the processes Over the last decade, several groups have shown that TFEB overexpression improves lysosomal trafficking, autophagosomal-lysosomal fusion and exocytosis, in a number of LSD and neurodegenerative storage disorder models. [193] [194] [195] [196] These "proof of concept" experiments route on promoting nuclear translocation of members of the MiT/TFE family of transcription factors to increase autophagy, which might alleviate the lysosomal accumulation of undegraded materials characteristic of the diseases. However, a word of caution has to be raised here because it is also known that TFEB and other members of the MiT-TFE family display oncogenic features. [197] [198] [199] Nevertheless, recent reports on trehalose, a natural sugar known to induce TFEB expression, indicate that treatment reduces disease burden in a number of pre-clinical LSD models. 196, 200 Importantly, trehalose treatment significantly reduced the number of large autophagic vacuoles in the cortex and cerebellum (neurons and microglia) of MPS IIIB mice. 200 Since the accumulation of large autophagic vacuoles is considered as the primary cause of the neuronal degeneration observed, these results serve as an example that therapies triggering organelle size reduction could be efficient tools in the treatment of LSD. Expanding on the TFEB concept, inhibitors targeting mTORC1 on lysosomes could be relevant treatment options in the future. 201 Following the precedent created by small molecular weight compounds targeting the cystic fibrosis transmembrane conductance regulator (CFTR) channel, scientists at the University of Munich have targeted TRPML1, the endolysosomal cation channel mutated in Mucolipidosis type IV. 202 The authors identified a small molecule that restores the phenotype of a specific subset of TRPML1 mutations. 7.2 | What is the contribution of lysosomal size to disease?
A decade ago, it was proposed that LSD pathophysiology might root on reduced fusion efficiency between autophagosomes and lysosomes. 146 This block in autophagy would activate a compensatory feedback mechanism increasing autophagosome formation (Figure 3 right side, annotated in green as I). The variation in the severity of the symptoms expressed in the different LSD would depend on the strength of the fusion block and on the extent of the expansion of autophagosome/ lysosomal compartments generated as a consequence. 150 A second hypothesis raised to explain LSD progression, is based on impaired lysosomal reformation (Figure 3 right side, annotated in green as II). In brief, fibroblasts from patients with different LSD (Scheie syndrome, Fabry disease and Aspartylglucosaminuria) show compromised mTOR reactivation and ALR defects. 22 The tight interplay between lysosomal catabolism and ALR would explain why minor defects in either of two processes are amplified in a positive feedback cycle, eventually triggering the progressive pathology of LSD. 205 These hypotheses have two aspects in common. First, independently of the initiating mechanism, the secondary progressive accumulation of nondegradable cargo (from damaged organelles to ubiquitinated proteins) seems to play a pivotal role in LSD pathology.
Second, both of the mechanisms proposed control the organelle's size.
In Figure 3 we present a model that tries to summarize the working hypotheses underlying LSD pathophysiology, including fusion, fission and acidification defects, cargo accumulation and increased organelle size.
The emerging mechanistic and phenotypical similarities between LSD and other diseases, in particular those with increased lysosomal size, highlight the need to reconsider disease boundaries. 191 In all of these disorders, independently of the initiating factor, the intertwined dynamic balance between fission, fusion, and number of lysosomes is impaired and actively contributes to disease progression. To cut it short, lysosomal size does indeed matter.
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